Top of this page
Skip navigation, go straight to the content
Investor News
- UCB's Cimzia® filed with EMEA for treatment of rheumatoid arthritis 01-July-2008
- UCB's Vimpat™ recommended for approval in Europe for epilepsy 26-June-2008
- First results for Phase IIa data of UCB's lacosamide for treatment of fibromyalgia 24-June-2008
- Otsuka and UCB agreed to co-develop and co-promote Keppra® and Cimzia® in Japan 10-June-2008
- US FDA grants pediatric exclusivity for UCB's Keppra® 06-June-2008
- UCB to implement full cold-chain for Neupro® 04-June-2008
- Cimzia® data presented at the Digestive Disease Week (DDW) meeting 20-May-2008
- Interim Report: UCB off to a good start in 2008 15-May-2008
- Neupro® recommended for approval in Europe for Restless Legs Syndrome 25-April-2008
- UCB's CEO Confirms Company Strategy 24-April-2008
- Cimzia® Approved in the US for the Treatment of Moderate to Severe Crohn's Disease 22-April-2008
- Phase II results for CDP791 in non-small cell lung cancer support further clinical development 31-March-2008
- New member of UCB's Board of Directors 28-March-2008
- CHMP Upholds Negative Opinion for the EU Application for Cimzia® in the Treatment of Crohn's Disease 20-March-2008
- UCB advises US-physicians to down-titrate patients on Neupro® in view of out-of-stock situation in the US 20-March-2008
- FDA Statement relating to Tussionex 12-March-2008
- UCB: Early Data on Cimzia® from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients 04-March-2008
- Changes in UCB's Executive Committee 03-March-2008
- UCB: Full Year 2007 Financial Results 29-February-2008
- FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria 19-February-2008
- FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis 06-February-2008
- Keppra XR(TM) Extended- Release Tablets Filed with the FDA 16-January-2008
- UCB on Track 14-December-2007
- Changes in UCB's Board of Directors 14-December-2007
- Neupro® Filed with the FDA for the Treatment of Restless Legs Syndrome 13-December-2007
- Neupro® Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease 13-December-2007
- New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain 11-December-2007
- Neupro® Filed in Europe for the Treatment of Restless Legs Syndrome 05-December-2007
- UCB Announces Positive Phase III Trial Results for Keppra XR(TM) 03-December-2007
- UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 29-November-2007
- UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain 29-November-2007
- UCB to Appeal European Negative Opinion on CIMZIA® for the Treatment of Patients with Crohn's Disease 16-November-2007
- UCB Announces Initiation of Phase III Clinical Programme for RikeltaTM (brivaracetam) as Adjunctive Treatment in Partial-Onset Epilepsy 26-October-2007
- UCB celebrates the Grand opening of a new facility in Shannon in presence of H.M. King Albert II, and appeals to build on Belgium's strong innovative capacities 10-October-2007
- UCB's Keppra® patent litigation in the US settled 04-October-2007
- New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USA 02-October-2007
- UCB Announces Submission of Lacosamide Marketing Application for Diabetic Neuropathic Pain 17-August-2007
- UCB: First Half-Year 2007 Financial Results* 26-July-2007
- UCB announces The U.S. Launch of Neupro® (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease 16-July-2007
- UCB APPOINTS DETLEF THIELGEN AS CHIEF FINANCIAL OFFICER 16-July-2007
- UCB announces The U.S. Launch of Neupro® (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease 16-July-2007
- UCB Announces Registration of Domination and Profit Transfer Agreement Allowing Full Integration of Schwarz Pharma 13-July-2007
- Luc Missorten has decided to pursue new opportunities 02-July-2007
- UCB and Biogen Idec's oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis 26-June-2007
- CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis 14-June-2007
- FDA approves XYZAL(R) tablets for the treatment of seasonal and year round allergies, and chronic urticaria 29-May-2007
- UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease 22-May-2007
- Statement of the Chief Executive Officer of UCB to the 2007 Annual General Shareholders Meeting 26-April-2007
- UCB Announces Positive Top-Line Phase III Results for Keppra® as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age 20-April-2007
- UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US 23-March-2007
- Keppra® Approved for US Epilepsy Patients with One of the Most Debilitating Seizure Types 20-March-2007
- New European Approval for Xyrem® Provides Significant Advance in the Treatment of Narcolepsy 12-March-2007
- UCB has sold successfully its stake in Cytec Industries 08-March-2007
- UCB Full-Year 2006 Financial Results 28-February-2007
- Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis 23-February-2007
- Financière de Tubize strengthens its shareholding in UCB 09-February-2007
- UCB gains global rights pertaining to VEGFR-2 for CDP-791 06-February-2007
- European Medicines Agency Adopts Positive Opinion Recommending Approval of Xyrem® for the Treatment of Narcolepsy with Cataplexy in Adult Patients 25-January-2007
- MORE EUROPEAN PATIENTS WITH EPILEPSY TO BENEFIT FROM KEPPRA® 16-January-2007
- UCB AND SCHWARZ PHARMA START PREPARATIONS FOR DOMINATION AND PROFIT TRANSFER AGREEMENT 12-January-2007
- Admission to listing on Eurolist by Euronext Brussels of 1,767,184 new shares of UCB issued 08-January-2007
- Pierre Fabre acquires Over-The-Counter Business of UCB in France, Benelux, Switzerland and Greece 08-January-2007
- SUCCESSFUL TAKEOVER OF SCHWARZ PHARMA BY UCB 04-January-2007
- UCB announces positive results from two new phase III studies in rheumatoid arthritis and provides update on the status of US approval for CIMZIATM in the treatment of Crohn's disease 22-December-2006
- Admission to listing on Eurolist by Euronext Brussels of 35,565,268 new shares of UCB issued 15-December-2006
- NEW CEO OF SCHWARZ PHARMA JOINS EXECUTIVE COMMITTEE OF UCB 14-December-2006
- UCB ANNOUNCES COMMENCEMENT OF FINAL ACCEPTANCE PERIOD FOR TAKEOVER OF SCHWARZ PHARMA 14-December-2006
- Significant acceptances by SCHWARZ shareholders for UCB tender offer 11-December-2006
- CHMP Adopts Positive Opinion Recommending Approval of Keppra® as Adjunctive Therapy in the Treatment of Primary Generalised Tonic-Clonic Seizures 23-November-2006
- UCB OBTAINS EUROPEAN ANTITRUST CLEARANCE FOR TAKE-OVER OF SCHWARZ PHARMA 21-November-2006
- UCB ANNOUNCES COMMENCEMENT OF ACCEPTANCE PERIOD FOR TAKEOVER OF SCHWARZ PHARMA 10-November-2006
- UCB EXPANDS TO CANADA 07-November-2006
- New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease 23-October-2006
- New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab 23-October-2006
- UCB Extraordinary Shareholders' General Meeting Approved Capital Increase 23-October-2006
- UCB and Jazz Pharmaceuticals announce expansion of Xyrem® license agreement to include fibromyalgia syndrome 03-October-2006
- UCB and Biogen Idec to Collaborate on Oral Multiple Sclerosis Therapy 02-October-2006
- UCB hosts its first Research and Development Day 26-September-2006
- UCB ANNOUNCES PROPOSED ACQUISITION OF SCHWARZ PHARMA FOR CASH AND SHARES, VALUING SCHWARZ PHARMA AT 4.4 BILLION EUROS 25-September-2006
- UCB - video interview 25-September-2006
- FINANCIERE DE TUBIZE - UCB's proposed acquisition of Schwarz Pharma 25-September-2006
- UCB and sanofi-aventis sign a co-promotion agreement for Xyzal® in the United States 25-September-2006
- UCB Awards Professorial Chair in Management of Inflammatory Bowel Disease at the Katholieke Universiteit Leuven, Belgium 15-September-2006
- FDA Approves Keppra® as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy 23-August-2006
- UCB Announces Agreement with Verus Pharmaceuticals for Commercialization of Twinject® in Europe 21-August-2006
- Key Approval for Keppra® Offers New Treatment Option for Newly Diagnosed Epilepsy Patients 18-August-2006
- FDA Approves Keppra® Intravenous Formulation 02-August-2006
- UCB First Half-Year 2006 Financial Results 27-July-2006
- CIMZIA(TM) Shows Promise in Treatment of Psoriasis 18-July-2006
- A Key Regulatory Milestone for Keppra® 03-July-2006
- Statement of the Chief Executive Officer to the Shareholders 13-June-2006
- UCB Award for Neuroscientific Research Presented to leading Belgian Neuroscience Group 13-June-2006
- UCB SELLS TO ADAMS RESPIRATORY THERAPEUTICS OTC DELSYM® 12-HOUR COUGH SUPPRESSANT LIQUIDS 25-May-2006
- UCB Completes Mutual Recognition Procedure for Equasym(TM) XL 24-May-2006
- New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile 22-May-2006
- Invitation: Conference call 19-May-2006
- European Commission Approves Keppra® for Use as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy 15-May-2006
- UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab 10-May-2006
- UCB Submits Marketing Authorisation Application in Europe for CIMZIATM, a New Crohn's Disease Therapy 28-April-2006
- UCB: Two European Regulatory Milestones for Keppra® 26-April-2006
- UCB transfers back to Recordati the rights for the sale of Corifeo® (Lercanidipine) in Germany 24-April-2006
- UCB - 2005 Annual Report on-line 31-March-2006
- UCB - 2005 Annual Report on-line 31-March-2006
- UCB Full-Year 2005 Financial Results 14-March-2006
- UCB - live analyst presentation 14-March-2006
- UCB Alert: 2005 Full Year Results on Tuesday, March 14, 2006 10-March-2006
- UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease 02-March-2006
- UCB Licenses Sepracor U.S. patents for antihistamine Levocetirizine 23-February-2006
- UCB Receives EMEA Positive Opinion and FDA Approvable Letter for Keppra® (levetiracetam) Intravenous Administration 03-February-2006
- UCB Receives EMEA Positive Opinion and FDA Approvable Letter for Keppra® (levetiracetam) Intravenous Administration 03-February-2006
- UCB confirms good 2005 performance of Zyrtec in US and Xyzal 19-January-2006
- Lonza Acquires the Bioproducts Manufacturing Division of UCB 17-January-2006
- UCB confirms positive outlook for 2005 12-December-2005
- Xyrem® is Launched in Germany for the Treatment of Cataplexy in Adults with Narcolepsy 08-December-2005
- New Data on the Use of Keppra® (levetiracetam) as Adjunctive Treatment in Idiopathic Generalised Epilepsy Patients with Primary Generalised Tonic-Clonic Seizures 06-December-2005
- Two Senior Pharma Executives as New Members of UCB's Executive Committee 22-November-2005
- Actelion and UCB enter into assignment and license agreement for Zavesca® (miglustat) 17-November-2005
- UCB Receives FDA Orphan Drug Designation for Brivaracetam for the Treatment of Symptomatic Myoclonus 09-November-2005
- UCB Reports Positive Clinical Trial Results for Keppra® as Adjunctive Therapy in the Treatment of Primary Generalised Tonic-Clonic Seizures 27-October-2005
- UCB confirms good performance of Zyrtec in US and Xyzal 20-October-2005
- UCB: Phase III study shows CIMZIA(TM) is an effective and well-tolerated treatment for Crohn's disease 18-October-2005
- European Commission Approves Use of UCB's Anti-Epileptic Keppra® as Adjunctive Therapy in Children Four Years of Age and Older with Partial-Onset Seizures 22-September-2005
- UCB'S ANTI-EPILECTIC KEPPRA® MEETS PRIMARY END-POINT IN MONOTHERAPY TRIAL 15-September-2005
- UCB Announces Divestment of Celltech Manufacturing Services - a UCB Subsidiary for Contract Manufacturing 26-August-2005
- UCB And Imclone Systems Enter Into Worldwide Partnership For Cdp-791, A Novel Investigational Therapy Targeting The Development Of Tumor Vasculature 16-August-2005
- UCB Reports Positive Opinion from EMEA for Paediatric Indication for Keppra® 01-August-2005
- UCB first half-year 2005 results including unaudited Half-Year Financial Report 27-July-2005
- UCB first half-year 2005 results 27-July-2005
- CIMZIA(TM) demonstrates significant positive results in its two pivotal phase III Crohn's disease trials 26-July-2005
- UCB Receives Positive Opinion from European Authorities for Orphan Designation of Brivaracetam for the Treatment of Progressive Myoclonic Epilepsies 25-July-2005
- UCB Confirms Solid First Half Zyrtec Sales in USA 20-July-2005
- UCB sells its food diagnostics business to Neogen 06-July-2005
- Positive opinion for UCB's Xyrem® for the treatment of cataplexy in adults with narcolepsy 29-June-2005
- FDA Approves UCB's Keppra® for Use in Childhood Epilepsy 24-June-2005
- UCB Confirms Positive Financial Outlook for 2005 14-June-2005
- UCB and Lonza Enter Into a Strategic Bio-Manufacturing Alliance 13-May-2005
- UCB Confirms Strong Quarterly Sales In The Us Xyzal Sells More Than Zyrtec In Europe 19-April-2005
- Of Co-Distributor For Zyrtec® In Japan 18-April-2005
- UCB Announces European Launch Of Kentera(TM) The First European Transdermal Oxybutynin Treatment For Overactive Bladder 18-April-2005
- First evidence of efficacy for UCB's Keppra®* in the adjunctive treatment of myoclonic seizures 31-March-2005
- UCB Group confirms its previously announced 2004 results and provides IFRS reconciliation and product update 23-March-2005
- UCB: Closing Of The Sale Of Its Surface Specialties Division 01-March-2005
- FDA grants priority review to levetiracetam for use in childhood epilepsy 17-February-2005
- UCB Group preliminary full-year 2004 results 07-February-2005
- UCB Pharma enters into agreement to collaborate on two Biotherapeutic Inflammation Programs with Millennium 25-January-2005
- UCB Confirms Annual Zyrtec Sales In The US - Xyzal Sells More Than Zyrtec In Europe 19-January-2005
